ReviewCureus2025
Pediatric-Type Diffuse Low-Grade Gliomas: A Subgroup Defined by Peculiar Molecular Features and Distinct Prognostic Outcomes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite their biological and molecular heterogeneity, pediatric-type diffuse low-grade gliomas exhibit significantly different prognostic outcomes compared to their adult-type counterparts. Accurate diagnosis is essential to avoid aggressive overtreatment and to enable exploration of relevant molecular targets for personalized therapy. This review provides a comprehensive overview of the epidemiology, clinical presentation, radiologic findings, histopathologic features, and key molecular events characterizing the newly defined WHO subgroup "pediatric-type diffuse low-grade gliomas." The review also outlines the conventional treatment modalities, including surgery, chemotherapy, and radiotherapy, while discussing their limitations and adverse effects. In addition, emerging therapeutic strategies based on molecular targets are briefly highlighted, offering a glimpse into current clinical trials and FDA-approved targeted therapies. Data were retrieved from credible scientific sources including PubMed, Google Scholar, and the 2021 WHO Classification of Central Nervous System Tumors. The newly established molecular subgroup comprises four distinct entities: 1) Diffuse astrocytoma, MYB or MYBL1-altered; 2) Angiocentric glioma; 3) Polymorphous low-grade neuroepithelial tumor of the young; and 4) Diffuse low-grade glioma, MAPK pathway-altered. Unlike circumscribed astrocytic gliomas, these tumors exhibit partial infiltrative behavior. However, they tend to have a more favorable prognosis than adult-type diffuse gliomas, IDH-mutant. Circumscribed gliomas are typically managed with gross total resection and show a lower recurrence rate in comparison to this newly recognized subgroup. While surgical resection remains curative for small, superficial tumors, deeper or more infiltrative variants may recur following subtotal resection. A thorough understanding of the clinicopathological and molecular features of these gliomas is imperative for accurate classification and appropriate therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.